Gastric-type Endocervical AdenocarcinomaSURGENCT07026825
Surgical Resection Enhances Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Study
An observational study of Gastric-type Endocervical Adenocarcinoma, run by Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center.
Trial summary
This retrospective cohort study analyzes the effect of surgical resection on survival outcomes in patients with gastric-type endocervical adenocarcinoma (GAS), using data from the SEER database (2000-2021). Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Gastric-type Endocervical Adenocarcinoma
- How many people
- 308 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2000to 30 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: This study enrolled patients aged 18 years and older with histologically confirmed gastric-type endocervical adenocarcinoma and no prior history of other malignancies.
Who may be able to join
- Histologically confirmed gastric-type endocervical adenocarcinoma Cervix as the first primary site Diagnosis between 2000 and 2021
Who cannot join
- Incomplete survival or treatment data Diagnosis not confirmed microscopically
About this study
Official title: Surgical Resection Improves Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Propensity-Matched Cohort Study
This retrospective cohort study analyzes the effect of surgical resection on survival outcomes in patients with gastric-type endocervical adenocarcinoma (GAS), using data from the SEER database (2000-2021). Propensity score matching and multivariable Cox regression were used to compare overall survival (OS) and tumor-specific survival (TSS) between patients who underwent surgery and those who did not. The study aims to determine whether primary tumor resection is associated with improved survival across tumor sizes and stages.
Read the detailed description
The study utilized de-identified data from the SEER program encompassing women aged ≥18 with histologically confirmed gastric-type endocervical adenocarcinoma between 2000 and 2021. The primary endpoints were overall survival and tumor-specific survival. Statistical analyses included multivariable Cox regression, propensity score matching (2:1), and inverse probability of treatment weighting (IPTW). Subgroup analyses were performed based on FIGO stage and tumor size (>4 cm). A total of 308 eligible cases were included. No patient interaction or clinical intervention occurred.
- Conditions
- Gastric-type Endocervical Adenocarcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| surgical Resection Group | Participants in this group undergo standard surgical resection aimed at the complete or partial removal of tumor tissue. The type of surgery-open or minimally invasive-is determined based on the patient's clinical condition and the surgeon's judgment. Preoperative and/or postoperative adjuvant therapies, such as chemotherapy or radiotherapy, may be administered to enhance treatment efficacy. | |
| Non-Surgical Management Group | Participants in this group receive standard non-surgical treatments, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy. The specific treatment regimen is tailored to the patient's condition and determined by the treating physician, aiming to control tumor progression, alleviate symptoms, and improve quality of life. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Outcome
Overall Survival (OS)
Measured: Time from diagnosis to death from any cause Up to 22 years (2000-2022)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2025
- Study start1 Jan 2000
- Primary completion30 Dec 2021
- Study completion30 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric-type Endocervical AdenocarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 308 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07026825
- Sponsor's protocol ID
- JS2024-32-1
- Acronym
- SURGE
- Status last verified
- Jun 2025
- First submitted
- 10 Jun 2025
- Last updated
- 18 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared due to concerns regarding participant privacy and confidentiality, as well as the absence of participant consent for data sharing.
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surgical Resection Improves Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Propensity-Matched Cohort Study
- ClinicalTrials.gov ID
- NCT07026825
- Acronym / sponsor ID
- SURGE / JS2024-32-1
- Conditions
- Gastric-type Endocervical Adenocarcinoma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 308 participants (actual)
- Lead sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterUniversity, hospital or other
- Study start
- 1 Jan 2000 (actual)
- Primary completion
- 30 Dec 2021 (actual)
- Study completion
- 30 Dec 2022 (actual)
- First posted
- 18 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective cohort study analyzes the effect of surgical resection on survival outcomes in patients with gastric-type endocervical adenocarcinoma (GAS), using data from the SEER database (2000-2021). Propensity score matching and multivariable Cox regression were used to compare overall survival (OS) and tumor-specific survival (TSS) between patients who underwent surgery and those who did not. The study aims to determine whether primary tumor resection is associated with improved survival across tumor sizes and stages.
Detailed description
The study utilized de-identified data from the SEER program encompassing women aged ≥18 with histologically confirmed gastric-type endocervical adenocarcinoma between 2000 and 2021. The primary endpoints were overall survival and tumor-specific survival. Statistical analyses included multivariable Cox regression, propensity score matching (2:1), and inverse probability of treatment weighting (IPTW). Subgroup analyses were performed based on FIGO stage and tumor size (>4 cm). A total of 308 eligible cases were included. No patient interaction or clinical intervention occurred.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| surgical Resection Group | – | –Participants in this group undergo standard surgical resection aimed at the complete or partial removal of tumor tissue. The type of surgery-open or minimally invasive-is determined based on the patient's clinical condition and the surgeon's judgment. Preoperative and/or postoperative adjuvant therapies, such as chemotherapy or radiotherapy, may be administered to enhance treatment efficacy. |
| Non-Surgical Management Group | – | –Participants in this group receive standard non-surgical treatments, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy. The specific treatment regimen is tailored to the patient's condition and determined by the treating physician, aiming to control tumor progression, alleviate symptoms, and improve quality of life. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study enrolled patients aged 18 years and older with histologically confirmed gastric-type endocervical adenocarcinoma and no prior history of other malignancies.
Key inclusion criteria (1 listed)
- Histologically confirmed gastric-type endocervical adenocarcinoma Cervix as the first primary site Diagnosis between 2000 and 2021
Key exclusion criteria (1 listed)
- Incomplete survival or treatment data Diagnosis not confirmed microscopically
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Outcome
Time frame: Time from diagnosis to death from any cause Up to 22 years (2000-2022)
Overall Survival (OS)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2025.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared due to concerns regarding participant privacy and confidentiality, as well as the absence of participant consent for data sharing.
Related trials for Gastric-type Endocervical Adenocarcinoma
Active, not recruitingPhase 2
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
RecruitingPhase 2
IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial
Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma
Not yet recruitingPhase 3
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
Gastric-type Endocervical Adenocarcinoma, Cervical Cancer
RecruitingPhase 2
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric-type Endocervical Adenocarcinoma, run by Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Outcome (time frame: Time from diagnosis to death from any cause Up to 22 years (2000-2022)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2025.